Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)

PHASE2UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2022

Conditions
Coronary Artery DiseaseMyocardial Ischemia
Interventions
DEVICE

AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold

Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.

Trial Locations (13)

Unknown

NOT_YET_RECRUITING

Clinica de Marly, Bogotá

RECRUITING

Instituto del Corazon, Bucaramanga

RECRUITING

EMMSA Clinica Especializada, Medellín

RECRUITING

Angiografia De Occidente S.A., Santiago de Cali

NOT_YET_RECRUITING

Azienda Policlinico-Vittorio Emanuele, Universita di Catania, Catania

NOT_YET_RECRUITING

Azienda Ospedaliero Universitaria Careggi, Florence

NOT_YET_RECRUITING

Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan

NOT_YET_RECRUITING

IRCCS Instituto Clinico Humanitas, Milan

NOT_YET_RECRUITING

Ospedale San Raffaele, Milan

NOT_YET_RECRUITING

Policlinico San Donato, Milan

NOT_YET_RECRUITING

A. O. U. Federico II˚ Policlinico, Napoli

NOT_YET_RECRUITING

Policlinico Universitario, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua

NOT_YET_RECRUITING

A. O. Ordine Mauriziano Umberto I, Torino

Sponsors
All Listed Sponsors
lead

Amaranth Medical Inc.

INDUSTRY

NCT02900937 - Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) | Biotech Hunter | Biotech Hunter